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Background
In the UK it is estimated that about 5% patients with
dementia above the age of 60 suffer from Normal pressure
hydrocephalus (NPH). This 5% could represent up to
24,000 people who may be suitable for assessment for
treatment. Awareness of this condition is constantly rising
both among doctors and patients. A recognised difficulty
is the confirmation of the diagnosis and selection of those
patients who will benefit from treatment. Despite emerg-
ing knowledge of over 40 years, the results of patient selec-
tion and shunt insertion have not improved significantly.
Since the historic paper by Hakim and Adams in 1965, a
great deal of further research has accumulated. Patients
are currently classified into those whose NPH has a
known cause and an idiopathic group (INPH). Table 1
highlights the key research findings so far.
Patient Selection
No single test is predictive to determine the shunt
responders. Over the years several combinations of tests
have been used to predict those who will respond to a
shunt operation. Surgery is believed to benefit 50–70% of
patients where there is a known cause, and 30–50% where
the cause is idiopathic if identified correctly. It is equally
important to identify patients unlikely to benefit. Shunt-
ing, particularly in elderly patients, is associated with a
significant incidence of both acute and cumulative longer-
term complication. Only a few papers report the extended
follow-up of patients and the value of the predicting fac-
tors in the long term. A guide to some of the tests and pre-
dictive feature identified in the literature is summarised in
Table 2.
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Table 1: 
1965 First paper to mention about clinical symptoms and signs of NPH Adams et al.
1960's Isotope Scintigraphy -
1970 Simple Constant-infusion manometric test for measurement of CSF absorption Katzman and Hassey
1974 Characters of dementia Albert et al.
1977 CT scan and ICP monitoring in hydrocephalus with dementia Crocard et al.
1982 CSF fluid tap test Wikkelso et al.
1982 Conductance to outflow of CSF in normal pressure hydrocephalus Borgesen et al.
1986 CSF drainage test (120–500 ml for 5 days) Dilauro
1986 Improvement in neuropsychological tests was observed in patients with a Cout of <0.051 Thomsen et al.
1987 Cerebral blood flow in NPH Mamo et al.
1988 Phosphorus MR spectra in NPH – reversible periventricular acidosis Arnold et al.
1988 External ventricular drain of 300 ml CSF for 5 days Haan et al.
1989 Third ventriculostomy in the treatment of NPH (microsurgical) Magnaes et al.
1993 Resistance to CSF outflow in prediction of outcome after shunting Delwel et al.
1993 High resolution SPECT in NPH before and after shunting Waldemar et al.
1996 MR CSF flow studies in NPH Bradley et al.
1999 CANTAB – Neuropsychological application in NPH Iddon et al.Page 1 of 2
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Few studies have examined the long-term prognosis for
those with treated and untreated NPH. Indeed, the recent
Cochrane review (2002) indicated that shunt insertion
was ineffective in treating NPH but this may be due to
inappropriate comparison groups and lack of class 1 evi-
dence. Tests revolving around CSF lumbar puncture, lum-
bar tap and drainage have been the main stay of assessing
likelihood to respond to treatment. But, how reliable is
this in predicting outcome? Since the disease is complex
and there may not be a gold standard test to predict shunt
response, future efforts should be directed towards better
identification of the pathogenesis of idiopathic NPH.
Many CSF factors have been identify that can diagnose the
disease and predict outcome. MR CSF flow studies can
predict shunt responders and PET scans have been used to
detect peri-ventricular blood flow improvement post
shunt. Non-invasive methods of investigation and predic-
tion of outcome is being increasingly recognised. Treat-
ment has been challenged with ventriculostomy. Thus, it
is clear that further work needs to be conducted to
ascertain the best way of diagnosing patients likely to ben-
efit from surgery.
Table 2: 
CT Enlarged ventricles; periventricular hypodensities; flattened cortical sulci; small or absent perihippocampal fissure
MRI All of the above; especially small or absent perihippocampal fissure
Cerebral blood flow Reduction in frontal lobe BF, global reduction in cerebral metabolism, perventricular decreased BF, basal ganglia and 
thalamus reduced BF (Transcranial Doppler, SPECT)
Isotope Isotope in the ventricles remains static > 72 hours
Cisternography/ MRI with no distribution over the convexities
Removal of CSF External lumbar drain, lumbar puncture, external ventricular drain
ICP monitoring Increase in number, peak and pulse pressure beta waves
CSF markers Sr Alpha-1 antichymotripsin, Tau proteins, Sulfatides, neurofilament protein & GFAP, Myelin based protein, TNF-alpha, 
Lipocalin-type PG-D synthase, galaninPage 2 of 2
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